

March 03, 2025

To,
The Manager
Dept of Corporate Services
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400001

Dear Sir/Madam,

Subject : Allotment of Convertible Equity Warrants
Reference : Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Scrip Code : 511509

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform that consequent to the special resolution passed by the shareholders of the Company at an Extra-Ordinary General Meeting convened on Friday, February 07, 2025 for issuance of 1,00,00,000 convertible equity warrants and pursuant to the in-principle approval given by BSE Ltd vide their letter LOD/PREF/TT/FIP/1823/2024-25 dated February 17, 2025, the Stakeholders Relationship Committee at its meeting held today i.e. Monday, March 03, 2025 has approved the allotment of 22,223 (Twenty-Two Thousand Two Hundred and Twenty-Three only) convertible equity warrants at an Issue Price of Rs.45/- (Face Value of Rs.10/- and Premium of Rs.35/-) on preferential basis in accordance with SEBI (ICDR) Regulations, 2018, to the following persons on receipt of the subscription amount equivalent to 25% of the Issue Price:

S.No	Name of Allottees	Category	No. of Warrants Allotted
1	Antique Infotech Private Limited	Public	22,223
TOTAL			22,223

We would further like to state that fully paid-up equity shares of face value of Rs. 10/- each of the Company against each Warrant shall be allotted on receipt of balance 75% of the issue price for each Warrant. Pursuant to above allotment of Warrants, presently there is no change in the paid-up share capital of the Company.

The details as required under the Regulation 30 of the SEBI Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, is enclosed as Annexure I.

This is for your information and records.

Thanking You,
Yours faithfully
For Vivo Bio Tech Limited

A V Kiran
Company Secretary

Annexure-I

Details as required under Regulation 30 of the Listing Regulations read with Master Circular issued by SEBI vide circular no. SEBI/HO/CFD/PoD2/CIR/P/2023/120 dated July 11, 2023 (“Master Circular”).

S.No.	Particulars	Disclosure																													
1.	Type of securities proposed to be Issued	Fully Convertible Equity Warrants (“Warrants”)																													
2.	Type of issuance	Preferential Issue																													
3.	Outcome of the Subscription, type of issue, type of securities and total number of securities	<p>The following are details of outcome of subscription:</p> <table border="1"> <thead> <tr> <th>Preferential Issue of</th> <th>Issued</th> <th>Subscribed and allotted in this tranche</th> </tr> </thead> <tbody> <tr> <td>Warrants</td> <td>1,00,00,000</td> <td>22,223</td> </tr> </tbody> </table> <p>22,223 (Twenty-Two Thousand Two Hundred and Twenty-Three only) convertible equity warrants allotted at an Issue Price of Rs. 45/- (Face Value of Rs.10/- and Premium of Rs.35/-) on receipt of 25% subscription amount aggregating to Rs. 2,50,000/- (Rupees Two Lakh Fifty Thousand only).</p>	Preferential Issue of	Issued	Subscribed and allotted in this tranche	Warrants	1,00,00,000	22,223																							
Preferential Issue of	Issued	Subscribed and allotted in this tranche																													
Warrants	1,00,00,000	22,223																													
4.	Name and number of the Investor(s)	<table border="1"> <thead> <tr> <th>S.No</th> <th>Name of Allottees</th> <th>Category</th> <th>No. of Warrants Allotted</th> </tr> </thead> <tbody> <tr> <td>1</td> <td>Antique Infotech Private Limited</td> <td>Public</td> <td>22,223</td> </tr> <tr> <td colspan="3">TOTAL</td> <td>22,223</td> </tr> </tbody> </table>	S.No	Name of Allottees	Category	No. of Warrants Allotted	1	Antique Infotech Private Limited	Public	22,223	TOTAL			22,223																	
S.No	Name of Allottees	Category	No. of Warrants Allotted																												
1	Antique Infotech Private Limited	Public	22,223																												
TOTAL			22,223																												
5.	Post allotment of securities - outcome of the subscription.	<table border="1"> <thead> <tr> <th rowspan="2">Category</th> <th colspan="2">Pre preferential issue</th> <th colspan="2">Post preferential issue*</th> </tr> <tr> <th>No of Shares</th> <th>%</th> <th>No of Shares</th> <th>%</th> </tr> </thead> <tbody> <tr> <td>Promoters and Promoter Group (A)</td> <td>62,71,500</td> <td>38.88</td> <td>86,71,500</td> <td>36.70</td> </tr> <tr> <td>Public (B)</td> <td>98,57,020</td> <td>61.12</td> <td>1,49,57,020</td> <td>63.30</td> </tr> <tr> <td>Non-Promoter- Non Public Shareholding (C)</td> <td>0</td> <td>0</td> <td>0</td> <td>0</td> </tr> <tr> <td>Total (A) + (B)+(C)</td> <td>1,61,28,520</td> <td>100</td> <td>2,36,28,520</td> <td>100</td> </tr> </tbody> </table> <p>* The above post-issue shareholding is prepared assuming conversion of Warrants (allotted) on 20/02/2025 (21,33,333 warrants), 21/02/2025 (18,00,000 warrants), 24/02/2025 (35,44,444 warrants) and 03/03/2025 i.e., today (22,223 warrants) into equity shares, pursuant to this preferential issue.</p>	Category	Pre preferential issue		Post preferential issue*		No of Shares	%	No of Shares	%	Promoters and Promoter Group (A)	62,71,500	38.88	86,71,500	36.70	Public (B)	98,57,020	61.12	1,49,57,020	63.30	Non-Promoter- Non Public Shareholding (C)	0	0	0	0	Total (A) + (B)+(C)	1,61,28,520	100	2,36,28,520	100
Category	Pre preferential issue			Post preferential issue*																											
	No of Shares	%	No of Shares	%																											
Promoters and Promoter Group (A)	62,71,500	38.88	86,71,500	36.70																											
Public (B)	98,57,020	61.12	1,49,57,020	63.30																											
Non-Promoter- Non Public Shareholding (C)	0	0	0	0																											
Total (A) + (B)+(C)	1,61,28,520	100	2,36,28,520	100																											
6.	Intimation on conversion of securities or on lapse of the tenure of the instrument	The tenure of the Warrants shall not exceed 18 (eighteen) months from the date of allotment. Each warrant would be convertible into 1 Equity Share and the rights attached to Warrants can be exercised in one or more tranches, within 18 (eighteen months) from the date of allotment of such warrants. In the event that a Warrant holder does not exercise the Warrants within a period of 18 (eighteen) months from the date of allotment of such warrants, the unexercised																													

Registered Office: #8-2-672/5&6, Ilyas Mohammed Khan Estate, 3rd Floor, Road No. 1, Banjara Hills, Hyderabad, India - 500 034.

Address of Preclinical Research Facility: Sy.No:349/A, Pregnapur Village, Gajwel Mandal, Siddipet District, Telangana, India, **Pin Code:** 502311

Email: investors@vivobio.com, contact@vivobio.com, **Phone:** 040-23313288, **Website:** www.vivobio.com, **CIN:** L65993TG1987PLC007163.

		Warrants shall lapse and the amount paid by that Warrant holder on such Warrants shall stand forfeited by the Company.
7.	Nature of Consideration	Cash
8.	Any cancellation or termination of proposal for issuance of securities including reasons thereof	Not applicable

Warrants have been allotted upon receipt of 25% of the total consideration (i.e receipt of Rs. 11.25/- per warrant - out of the total of Rs. 45/- per warrant) and are convertible into equal number of equity shares upon receipt of the balance amount i.e., Rs. 33.75/- per warrant, within the stipulated time.